Company InfoNewsInvestor InformationResearchDevelopmentCareersBusiness DevelopmentResourcesDrugs databaseBack to the home pageSearch  
Drugs database
Drugs A-Z

Brands A-Z

Drugs by categories

Drugs by manufacturer

Drugs by packager

Antibiotics for sale

Online Viagra bestellen in Nederland

Home / Drugs / Starting with P / Phenylpropanolamine
 
Phenylpropanolamine
 

Phenylpropanolamine has been withdrawn in Canada. In November 2000, the Food and Drug Administration (FDA) issued a public health advisory against the use of the drug.
BrandsAcutrim
Ami-Tex
Codimal
Conex
Contuss
Despec
Dexatrim
Dura-Vent
Gentab
Guaipax
Myminic
Nolex
Partuss
Phenoxine
Phenyldrine
Phenylfenesin
Propagest
Rhindecon
Rhymed
Snaplets
ULR
Vanex
CategoriesSympathomimetics
Appetite Depressants
Adrenergic alpha-Agonists
Nasal Decongestants
PackagersAmerisource Health Services Corp.
Boca Pharmacal
Breckenridge Pharmaceuticals
Bristol-Myers Squibb Co.
C.O. Truxton Inc.
Carlisle Laboratories Inc.
Century Pharmaceuticals Inc.
Chattem Chemicals Inc.
Corvit Pharmaceuticals
DHHS Program Support Center Supply Service Center
Direct Dispensing Inc.
Duramed
Econolab Inc.
Equipharm Inc.
Farmaquimia SA de CV
Generics Puerto Rico Inc.
Gm Pharmaceuticals Inc.
Golden State Medical Supply Inc.
H and H Laboratories
Hi Tech Pharmacal Co. Inc.
International Ethical Labs Inc.
Iopharm Laboratories Inc.
Kaiser Foundation Hospital
Kraft Pharmaceutical Co. Inc.
Lark Pharmaceuticals Inc.
Llorens Pharmaceutical
Long Island Pharmacal
Major Pharmaceuticals
Mallinckrodt Inc.
Mcgregor Pharmaceuticals Inc.
Midland Pharmaceutical LLC
Murfreesboro Pharmaceutical Nursing Supply
Nexgen Pharma Inc.
Norega Laboratories Inc.
Novartis AG
Pamlab LLC
Patient First Corp.
PD-Rx Pharmaceuticals Inc.
Pecos Pharmaceutical Inc.
Pharmaceutical Utilization Management Program VA Inc.
Pharmedix
Physicians Total Care Inc.
Prometic Pharma Inc.
Qualitest
Respa Pharmaceuticals Inc.
Sandhills Packaging Inc.
Sanofi-Aventis Inc.
Seatrace Pharmaceuticals Inc.
Southwood Pharmaceuticals
St Mary's Medical Park Pharmacy
Talbert Medical Management Corp.
Topco
Tri Med Laboratories Inc.
United Research Laboratories Inc.
Veratex Corp.
Vista Pharmaceuticals Inc.
Synonyms(+-)-Phenylpropanolamine
(+/-)-Norephedrin

indication

For the treatment of nasal congestion, control of urinary incontinence, priapism and obesity.

pharmacology

Phenylpropanolamine (PPA), a sympathomimetic agent structurally similar to pseudoephedrine, is used to treat nasal congestion. Phenylpropanolamine is found in appetite suppressant formulations and with guaifenesinin in cough-cold formulations. In 2000, the FDA requested that all drug companies discontinue marketing products containing phenylpropanolamine, due to an increased risk of hemorrhagic stroke in women who used phenylpropanolamine.

mechanism of action

Phenylpropanolamine acts directly on alpha- and, to a lesser degree, beta-adrenergic receptors in the mucosa of the respiratory tract. Stimulation of alpha-adrenergic receptors produces vasoconstriction, reduces tissue hyperemia, edema, and nasal congestion, and increases nasal airway patency. PPA indirectly stimulates beta-receptors, producing tachycardia and a positive inotropic effect.

toxicity

May induce ventricular extrasystoles and short paroxysms of ventricular tachycardia, a sensation of fullness in the head and tingling of the extremities; LD50=1490mg/kg (orally in rat)

biotransformation

Hepatic

absorption

Reduced bioavailability (about 38%) from gastrointestinal tract because of first pass metabolism by monoamine oxidase in the stomach and liver.

half life

2.1 to 3.4 hours.

drug interactions

Acetophenazine: Decreased anorexic effect, may increase psychotic symptoms

Alseroxylon: Increased arterial pressure

Amitriptyline: The tricyclic antidepressant, amitriptyline, increases the sympathomimetic effect of phenylpropanolamine.

Amoxapine: The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of phenylpropanolamine.

Bromocriptine: The sympathomimetic, phenylpropanolamine, increases the toxicity of bromocriptine.

Chlorpromazine: Decreased anorexic effect, may increase psychotic symptoms

Clomipramine: The tricyclic antidepressant, clomipramine, increases the sympathomimetic effect of phenylpropanolamine.

Deserpidine: Increased arterial pressure

Desipramine: The tricyclic antidepressant, desipramine, increases the sympathomimetic effect of phenylpropanolamine.

Doxepin: The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of phenylpropanolamine.

Ethopropazine: Decreased anorexic effect, may increase psychotic symptoms

Fluoxetine: Risk of serotoninergic syndrome

Fluphenazine: Decreased anorexic effect, may increase psychotic symptoms

Fluvoxamine: Risk of serotoninergic syndrome

Guanethidine: Phenylpropanolamine may decrease the effect of guanethidine.

Imipramine: The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of phenylpropanolamine.

Isocarboxazid: Increased arterial pressure

Linezolid: Possible increase of arterial pressure

Mesoridazine: Decreased anorexic effect, may increase psychotic symptoms

Methdilazine: Decreased anorexic effect, may increase psychotic symptoms

Methotrimeprazine: Decreased anorexic effect, may increase psychotic symptoms

Methyldopa: Increased arterial pressure

Midodrine: Increased arterial pressure

Moclobemide: Moclobemide increases the sympathomimetic effect of phenylpropanolamine.

Nortriptyline: The tricyclic antidepressant, nortriptyline, increases the sympathomimetic effect of phenylpropanolamine.

Pargyline: Increased arterial pressure

Paroxetine: Risk of serotoninergic syndrome

Perphenazine: Decreased anorexic effect, may increase psychotic symptoms

Phenelzine: Increased arterial pressure

Prochlorperazine: Decreased anorexic effect, may increase psychotic symptoms.

Promazine: Decreased anorexic effect, may increase psychotic symptoms

Promethazine: Decreased anorexic effect, may increase psychotic symptoms.

Propericiazine: Decreased anorexic effect, may increase psychotic symptoms.

Propiomazine: Decreased anorexic effect, may increase psychotic symptoms

Protriptyline: The tricyclic antidepressant, protriptyline, increases the sympathomimetic effect of phenylpropanolamine.

Rasagiline: Increased arterial pressure

Reserpine: Increased arterial pressure

Thiethylperazine: Decreased anorexic effect, may increase psychotic symptoms

Thioridazine: Decreased anorexic effect, may increase psychotic symptoms

Tranylcypromine: Increased arterial pressure

Trifluoperazine: Decreased anorexic effect, may increase psychotic symptoms

Triflupromazine: Decreased anorexic effect, may increase psychotic symptoms

Trimeprazine: Decreased anorexic effect, may increase psychotic symptoms

Trimipramine: The tricyclic antidepressant, trimipramine, increases the sympathomimetic effect of phenylpropanolamine.

Venlafaxine: Risk of serotoninergic syndrome